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Comparison of Midregional
Pro-Atrial and B-Type Natriuretic
Peptides in Chronic Heart Failure
Influencing Factors, Detection of Left Ventricular
Systolic Dysfunction, and Prediction of Death
Deddo Moertl, MD,* Rudolf Berger, MD,* Joachim Struck, PHD,‡ Andreas Gleiss, PHD,†
Alexandra Hammer, MD,* Nils G. Morgenthaler, MD,‡ Andreas Bergmann, PHD,‡
Martin Huelsmann, MD,* Richard Pacher, MD*
Vienna, Austria; and Hennigsdorf/Berlin, Germany
Objectives Midregional pro-atrial natriuretic peptide (MR-proANP) was assessed for the importance of influencing factors,
the ability to detect left ventricular systolic dysfunction, and the prognostic power compared with B-type natri-
uretic peptide (BNP) and amino-terminal pro–B-type natriuretic peptide (NT-proBNP) in chronic heart failure (HF).
Background MR-proANP is a biologically stable natriuretic peptide measured by a recently developed assay, with potential
advantages over conventional natriuretic peptides such as BNP and NT-proBNP.
Methods We measured MR-proANP, BNP, and NT-proBNP in 797 patients with chronic HF.
Results All 3 natriuretic peptides were independently influenced by left ventricular ejection fraction (LVEF), glomerular
filtration rate (GFR), and the presence of ankle edema. Area under receiver-operator characteristic curves for
detection of an LVEF 40% were similar between MR-proANP (0.799 [95% confidence interval (CI): 0.753 to
0.844]), BNP (0.803 [95% CI: 0.757 to 0.849]), and NT-proBNP (0.730 [95% CI: 0.681 to 0.778]). During a me-
dian observation time of 68 months, 492 (62%) patients died. In multiple Cox regression analysis each natri-
uretic peptide was the strongest prognostic parameter among various clinical variables. Proportion of explained
variation showed that NT-proANP (4.36%) was a significantly stronger predictor of death than both NT-proBNP
(2.47%, p  0.0001) and BNP (2.42%, p  0.0001).
Conclusions Despite similarities in influencing factors and detection of reduced LVEF, MR-proANP outperformed BNP and
NT-proBNP in the prediction of death. A new assay technology and the high biological stability of MR-proANP are
potential explanations for these findings. (J Am Coll Cardiol 2009;53:1783–90) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.057i
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rn heart failure (HF), plasma natriuretic peptide levels have
een established, not only as excellent diagnostic markers
1), but also for the assessment of the severity of disease (2)
nd prognosis (3). Atrial natriuretic peptide (ANP) and
-type natriuretic peptide (BNP) are synthesized in the
yocardium as their precursors proANP and proBNP,
hich are then cleaved into the corresponding biologically
rom the *Department of Cardiology and †Core Unit for Medical Statistics and
nformatics, Medical University of Vienna, Vienna, Austria; and the ‡B.R.A.H.M.S.
G, Department of Research, Hennigsdorf/Berlin, Germany. Dr. Bergmann is a
ember of the board of directors of and holds ownership in B.R.A.H.M.S. AG
MR-proANP). Drs. Struck and Morgenthaler are employees of B.R.A.H.M.S. AG.
rs. Bergmann and Struck hold patent rights to MR-proANP.l
Manuscript received November 29, 2008; revised manuscript received January 16,
009, accepted January 25, 2009.nactive amino-terminal segments of the precursor mole-
ules (amino-terminal pro-atrial natriuretic peptide [NT-
roANP] and amino-terminal pro–B-type natriuretic pep-
ide [NT-proBNP], respectively) and the biologically active
eptides (ANP and BNP). In both clinical routine and
esearch, B-type–related natriuretic peptides (BNP and
T-proBNP) are the most commonly determined natri-
retic peptides. However, both atrial and B-type–related
atriuretic peptides have their limitations. For example,
NP has a higher short-term variability (half-life: 12 to
2 min) than NT-proBNP (half-life: 60 to 90 min) (4).
n the other hand, NT-proBNP is subject to degrada-
ion and polymerization. Therefore, the amino-terminal
egion might be insufficiently accessible for assays (5,6),
eading to underestimation of NT-proBNP levels (7).
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MR-proANP in Chronic HF May 12, 2009:1783–90Whereas ANP has a far too
short half-life (2 to 5 min) for
clinical application (4,8), NT-
proANP has already been used
for diagnostic and prognostic
purposes in heart failure (9,10)
and seems more robust to vary-
ing levels of patient activity
(11). However, diagnostic and
prognostic performance of NT-
proANP has been reported to
be inferior compared to BNP/
NT-proBNP (12–14).
Such inferiority might have
been due to suboptimal assay de-
sign, though, not due to the ana-
lyte per se. NT-proANP can also
be subject to terminal truncations
(5), a fact that has not been con-
sidered in the assay designs previ-
ously used. Recently, a new sand-
wich assay for NT-proANP has
been developed, utilizing antibod-
ies against the midregion of
the molecule, thus termed midre-
gional pro-atrial natriuretic pep-
tide (MR-proANP), and which is
therefore robust against truncation
of the molecule (15).
To investigate whether these biochemical advantages of
R-proANP translate into advantages in clinical applica-
ion, we directly compared the performance of MR-
roANP, NT-proBNP, and BNP for the detection of left
entricular systolic dysfunction and the prediction of death
n patients with chronic HF due to systolic dysfunction.
ince glomerular filtration rate (GFR) is increasingly rec-
gnized as a major confounder of natriuretic peptide levels
16,17), we also evaluated the influence of GFR on their
iagnostic and prognostic properties.
ethods
tudy sample. Patients were included from previous
hronic HF studies conducted at our ambulatory heart
ailure unit at the Medical University of Vienna, Austria.
amples were collected between 1996 and 2003. Among
hese patients, whose residual plasma was frozen and stored
t80°C, we selected patients for this investigation accord-
ng to the following criteria: history of chronic HF due to
ystolic dysfunction; documented left ventricular ejection
raction (LVEF) by echocardiography, radionuclide ven-
riculography, or contrast ventriculography at the time of
lood sampling; documented history, demographic data,
linical status, standard laboratory parameters, and medica-
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
AUC  area under curve
BMI  body mass index
BNP  B-type natriuretic
peptide
GFR  glomerular filtration
rate
HF  heart failure
LVEF  left ventricular
ejection fraction
MR-proANP  midregional
pro-atrial natriuretic
peptide
NT-proANP  amino-
terminal pro-atrial
natriuretic peptide
NT-proBNP  amino-
terminal pro–B-type
natriuretic peptide
NYHA  New York Heart
Association
PEV  proportion of
explained variation
ROC  receiver-operating
characteristicion at the time of blood draw. The protocol was approved by the institutional ethics
ommittee.
nd point. The end point analyzed was all-cause death,
ith patients receiving a ventricular assist device or heart
ransplantation censored at time of surgery. Mortality data
ere obtained from the Austrian Central Office of Civil
egistration. End of follow-up was April 2006.
easurement of natriuretic peptides. All blood samples
ere centrifuged within 1 h after collection; the resulting
lasma was frozen at 80°C until analyzed in a blinded
ashion for this study. Natriuretic peptides were deter-
ined using commercially available assays (MR-proANP:
RAHMS AG, Hennigsdorf, Germany [15]; NT-
roBNP: Elecsys, Roche Diagnostics, Basel, Switzerland;
NP: Triage, Biosite, San Diego, California).
tatistical analysis. The GFR was estimated using the
ormula by Cockroft and Gault (18). For calculation and
eporting, variables were transformed as follows: BMI in
-point steps, GFR in 10 ml/min steps, and age in 10-year
teps. The LVEF was ranked according to the following
lasses: 50%, 40% to 49%, 30% to 39%, and 30%.
Categorical data are presented as numbers (percent), con-
inuous variables as mean  SD. Due to right-skewed distri-
utions, natriuretic peptides are presented as median and
uartiles, and enter the models described below as their natural
ogarithms. Comparisons between groups were performed
sing chi-square tests for categorical data and the Student t test
or unpaired continuous data. Pearson correlation coefficients
ere calculated for each combination of natriuretic peptides.
The influences of age, sex, body mass index (BMI),
VEF, GFR, and ankle edema on the level of BNP,
T-proBNP, or MR-proANP were investigated using a
ultiple linear regression model. The results are presented
y regression coefficients on the one hand and by propor-
ions of explained variation (PEVs) on the other. Since the
ependent variables of the regression models (the natriuretic
eptides) were log-transformed, regression results are given
s multiplicative factors, which are the exponentials of the
stimated regression coefficients. Whereas regression coef-
cients show the direction and strength of a potential
nfluence, PEVs allow for presentation and comparison of
he proportion of the variability observed in the outcome
hat is explained by various independent variables, and thus
heir prognostic importance. Partial PEVs are given for each
ariable, thus adjusting for the respective remaining vari-
bles in the model. PEVs were calculated and compared
ith the method by Heinze and Schemper (19) using the
onventional linear regression R2 as measure of importance.
or each natriuretic peptide, p values for all pairwise
omparisons were corrected for multiple testing using the
haffer method (20). To compare the influence of GFR on
atriuretic peptide levels, the respective regression coeffi-
ients of a multivariate and multiple linear regression model
ere tested for equality.
The ability of the natriuretic peptides to detect an LVEF
40% was assessed using receiver-operating characteristic
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May 12, 2009:1783–90 MR-proANP in Chronic HFROC) curves and expressed by the area under curve (AUC)
ith 95% confidence intervals, which were compared by the
ethod of DeLong et al. (21). A cutoff point was deter-
ined exploratively as the point on the ROC curve closest
o the upper left corner. In order to investigate whether each
atriuretic peptide’s influence on LVEF depends on the
FR level, the interaction term of GFR with each natri-
retic peptide was tested against 0 in multinomial logistic
egression models with LVEF as an ordered dependent
ariable and sex, age, and BMI as adjustment variables in
ddition to GFR and the natriuretic peptides.
In order to assess and compare the prognostic values of
ifferent parameters, univariate and multiple Cox propor-
ional hazard regression analyses were performed. To deter-
ine which of the natriuretic peptides were independent
redictors of death, we calculated adjusted multiple Cox
odels for each natriuretic peptide separately. For con-
ounding variables, we entered the following predictors of
eath in chronic HF as previously published in a systematic
eview (3): age, sex, GFR, the presence of diabetes mellitus,
ew York Heart Association (NYHA) functional class,
VEF, plasma sodium concentrations, BMI, systolic blood
ressure, and the presence of ankle edema.
Finally, a full model with all 3 natriuretic peptides and all
f the previously-listed predictors of death was calculated in
rder to determine which of the natriuretic peptides (if any)
emained independent predictors of death.
To investigate whether each natriuretic peptide’s influ-
nce on survival depends on the GFR level, the interaction
erm of GFR with each natriuretic peptide was tested
gainst 0. The relative importance of the 3 natriuretic
eptides to predict death was assessed by calculating the
EV. Testing for statistically significant differences between
he PEVs of each natriuretic peptide was performed as
reviously described (19).
The reported p values are the results of 2-sided tests;
alues of p  0.05 were considered to be statistically
ignificant. All analyses were performed using SAS version
.1 (SAS Institute Inc., Cary, North Carolina).
esults
atient characteristics. The study population included
97 patients with chronic HF comprising a wide range of
ges (15 to 84 years), nutritional status (BMI: 16 to 52
g/m2), renal function (GFR: 7 to 232 ml/min), and
everity of HF as reflected by NYHA functional class,
VEF, and natriuretic peptide levels. Sex-specific baseline
haracteristics are presented in Table 1.
actors influencing natriuretic peptide levels. Natriuretic
eptides were highly correlated with one another, with
orrelation coefficients (r) of 0.82 (MR-proANP with NT-
roBNP), 0.87 (MR-proANP with BNP), and 0.86 (NT-
roBNP with BNP; p  0.0001).
Multiple linear regression analysis showed that LVEF,
FR, and the presence of ankle edema were independent Nredictors of the 3 natriuretic peptides, whereas age and
MI were not. Sex was an independent predictor of
R-proANP and BNP, but not NT-proBNP (Table 2).
hen adjusted for the other 5 variables, a 1-class decline in
VEF (50%, 40% to 49%, 30% to 39%, and 30%)
orresponded to 39%, 48%, and 78% increases in MR-
roANP, NT-BNP, and BNP, respectively; a 10 ml/min
ecline in GFR corresponded to 15%, 18%, and 15%
ncreases, respectively; and patients with ankle edema had
7%, 110%, and 149% higher levels of MR-proANP,
T-proBNP, and BNP, respectively, than patients without.
Partial (after adjustment for the respective other 5 con-
ounding variables) PEVs showed that LVEF, GFR, and
he presence of ankle edema had significantly more influ-
nce on each natriuretic peptide than age, BMI, and sex
corrected p  0.05 for each comparison) (Fig. 1). Consis-
ently, the combination of only LVEF, GFR, and the
resence of ankle edema explained 38%, 33%, and 28% of
he variation of MR-proANP, BNP, and NT-proBNP,
espectively, whereas adding age, BMI, and sex did not
ignificantly increase the explained variation of the natri-
retic peptides (MR-proANP: 39%, BNP: 33%, NT-
roBNP: 28%). No difference in the influence of GFR on
evels of the 3 natriuretic peptide levels was found.
etection of severity of left ventricular systolic dysfunc-
ion. ROC curves (Fig. 2) of natriuretic peptides to detect an
VEF 40% showed that MR-proANP and BNP had a
igher accuracy than NT-proBNP (p  0.0001 for each
omparison), whereas no difference was found between MR-
roANP and BNP (p  0.7411). Respective optimized cutoff
oints with sensitivity and specificity are presented in Table 3.
dependence on GFR level of each natriuretic peptide’s
nfluence on LVEF could not be detected.
rediction of death. Median (lower, upper quartile)
ollow-up time was 68 (55, 77) months. A total of 492 patients
62%) died, 49 (6%) received a ventricular assist device, and 25
3%) received a heart transplantation as their first event.
All 3 natriuretic peptides were significant predictors of
eath, even after adjustment for the pre-defined confounders
Table 4). Every doubling of MR-proANP, NT-proBNP, and
NP levels increased the risk of death by 54%, 27%, and 23%,
espectively. When all 3 natriuretic peptides were entered in
he model, only MR-proANP remained an independent pre-
ictor of death, as did age, sex, NYHA functional class, LVEF,
nd systolic blood pressure, but not the BNPs or GFR. The
artial PEVs to predict death were significantly higher for
R-proANP (4.91%) than for NT-proBNP (3.12%) and
NP (2.78%) (Fig. 3). The influence of each natriuretic
eptide on death was not dependent on GFR.
Similar results were obtained for the prediction of car-
iovascular death (91% of all-cause death, data not shown).
iscussion
espite slight advantages for MR-proANP and BNP over
T-proBNP, all 3 natriuretic peptides performed similarly
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MR-proANP in Chronic HF May 12, 2009:1783–90n the assessment of LVEF. As regards prediction of death,
R-proANP clearly outperformed NT-proBNP and BNP.
enal dysfunction had a strong influence on levels of all 3
atriuretic peptides to a similar degree but had no impact on
heir diagnostic or prognostic performance.
actors influencing natriuretic peptide levels. Previous
orks have recognized a variety of noncardiac factors
aseline Demographics, Clinical Characteristics, and Therapy
Table 1 Baseline Demographics, Clinical Characteristics, and T
Demographics
Age (yrs)
Cause of heart failure
Ischemic
Comorbidity
Hypertension
Diabetes mellitus
Ankle edema
Atrial fibrillation
Clinical presentation
NYHA functional class (I, II, III, IV) 90 (14%), 165
LV systolic dysfunction (no, mild, moderate, severe) 42 (6%), 37 (6
Body mass index
BP systolic/diastolic (mm Hg) 1
HR (beats/min)
Glomerular filtration rate (ml/min)
Natriuretic peptides, median (Q1, Q3)
BNP (pg/ml)
NT-proBNP (pg/ml) 2
MR-proANP (mmol/l)
Therapy
Beta-blockers
ACE-I or ARB
Combination ACE-I/ARB and beta-blocker
Aldosterone antagonist
Combination ACE-I and beta-blocker
Diuretic (except aldosterone antagonist)
Digitalis
Antithrombotic/anticoagulant
ICD
CRT
ata are n (%) or mean  SD unless otherwise indicated. *p  0.01, †p  0.05 versus men.
ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin receptor-blocker; BNP B-
CD  implantable cardioverter-defibrillator; LV  left ventricular; MR-proANP  midregional pro-a
eart Association; Q1  lower quartile; Q3  upper quartile.
ultiple Linear Regression Analysis Assessing the Independent Infl
Table 2 Multiple Linear Regression Analysis Assessing the Ind
MR-proANP (r2  0.39)
Multiplication Factor p Value Multiplic
LVEF 1.39 0.0001 1
GFR 0.87 0.0001 0
Age 1.03 0.1730 0
BMI 0.96 0.4112 1
Sex 1.37 0.0001 1
Edema 1.77 0.0001 2
ultiplication factors are the exponentials of the estimated regression coefficients and represent
50%, 40% to 49%, 30% to 39%, and 30%), a 10 ml/min increase in GFR, a 10-year increase in age
BMI  body mass index; edema  presence of ankle edema; GFR  glomerular filtration rate; LVEF nfluencing natriuretic peptide levels, including age, sex,
MI, and renal function (22–24). In our study, all 3
atriuretic peptides were to a higher degree dependent on
VEF, GFR, and the presence of ankle edema, whereas
ge, BMI, and sex contributed only marginally to explain
atriuretic peptide levels. This supports the use of natri-
retic peptides as biomarkers for the severity of HF, since a
py
n  653) Women (n  144)
11 57 13
42%) 49 (34%)
49%) 76 (53%)
22%) 32 (22%)
16%) 23 (16%)
22%) 18 (13%)*
), 270 (41%), 128 (20%) 13 (9%), 27 (19%), 74 (51%), 30 (21%)
2 (23%), 422 (66%) 17 (12%), 14 (10%), 33 (23%), 80 (56%)†
4 26 5*
2/74 13 120 25/75 15
16 77 16
30 63 30†
133, 863) 385 (120, 866)
845, 4,888) 2,778 (867, 5,620)
121, 479) 217 (117, 405)
70%) 100 (69%)
95%) 127 (88%)*
67%) 91 (63%)
30%) 50 (35%)
67%) 91 (63%)
73%) 104 (72%)
60%) 66 (46%)*
62%) 74 (51%)†
12%) 9 (6%)†
7%) 16 (11%)
triuretic peptide; BP blood pressure; CRT cardiac resynchronization therapy; HR heart rate;
triuretic peptide; NT-proBNP  amino-terminal pro–B-type natriuretic peptide; NYHA  New York
e of Different Variables on Natriuretic Peptides
ent Influence of Different Variables on Natriuretic Peptides
BNP (r2  0.28) BNP (r2  0.33)
actor p Value Multiplication Factor p Value
0.0001 1.78 0.0001
0.0001 0.87 0.0001
0.3942 0.96 0.7243
0.6145 1.02 0.5114
0.2264 1.30 0.0238
0.0001 2.49 0.0001
ltiplicative change in the respective natriuretic peptide associated with a 1-class decline in LVEFhera
Men (
57
272 (
323 (
146 (
102 (
149 (
(25%
%), 15
27
16 2
75
82
388 (
,216 (
269 (
457 (
622 (
440 (
196 (
440 (
479 (
391 (
407 (
79 (
46 (
type nauenc
epend
NT-pro
ation F
.48
.85
.97
.04
.15
.10
the mu
, a 5-point increase in BMI, female sex, and the presence of ankle edema.
left ventricular ejection fraction; other abbreviations as in Table 1.
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May 12, 2009:1783–90 MR-proANP in Chronic HFecline in LVEF, fluid retention, and HF-associated dete-
ioration in renal function (the so-called cardiorenal syn-
rome) are all expressions of the progression of HF.
Age, sex, and BMI have been described as factors
nfluencing natriuretic peptide levels in subjects without
F, so it has been suggested that reference values should be
djusted to these confounders (25). Although this might be
elevant in diagnosing unknown HF (26), our data suggest
hat the influence of age, sex, and BMI is negligible in
atients with known chronic HF when other, more disease-
elated factors such as ventricular function, volume status,
nd renal function become relevant.
stimation of the severity of systolic dysfunction by
atriuretic peptides. MR-proANP, NT-proBNP, and
NP performed well in detecting a reduced LVEF (40%,
UCs from 0.73 to 0.80). The AUCs are on the same order
f magnitude as in previous reports evaluating the perfor-
ance to detect an LVEF 40% in patients with known
ardiac disease (14) but lower than in studies investigating
he usage of natriuretic peptides for the diagnosis of
nknown heart failure. A potential explanation for this
Figure 2 ROC Curves
Receiver-operator characteristic (ROC) curves for detection of an LVEF 40% by
MR-proANP (red line), BNP (green line), and NT-proBNP (blue line). Abbrevia-
tions as in Figure 1.
OC-Derived Optimized Cutoffalues for the Detection of LVEF <40%
Table 3 ROC-Derived Optimized CutoffValues for the Detection of LVEF <40%
Cutoff Sensitivity Specificity
MR-proANP (mmol/l) 122 67.3% 81.1%
NT-proBNP (pg/ml) 1,869 71.8% 62.0%
BNP (pg/ml) 218 80.9% 70.7%
ptimized cutoff values are defined as the point on the receiver-operating characteristic (ROC)Figure 1 Factors Influencing Natriuretic Peptides
Relative influence of left ventricular ejection fraction (LVEF), glomerular filtration
rate (GFR), the presence of ankle edema (edema), age, sex, and body mass
index (BMI) on levels of midregional pro-atrial natriuretic peptide (MR-proANP)
(A), B-type natriuretic peptide (BNP) (B), and amino-terminal pro–B-type natri-
uretic peptide (NT-proBNP) (C), as expressed by the partial proportion of
explained variation. LVEF, GFR, and edema had a significantly stronger influ-
ence than age, sex, and BMI on levels of all 3 natriuretic peptides.urves closest to the point of perfect discrimination (top left corner).
Abbreviations as in Tables 1 and 2.
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MR-proANP in Chronic HF May 12, 2009:1783–90nding is that HF treatment by reducing wall stress confounds
he relation between LVEF and natriuretic peptides found in
ntreated patients.
NT-proBNP performed slightly worse than the other 2
eptides, a difference that reached statistical significance due
o the large patient population but can be considered of
inor clinical relevance. Data on a differential influence of
enal function on natriuretic peptides, which might explain
he diagnostic inferiority of NT-proBNP compared with
NP, are conflicting (16,17). In our study, GFR had a
imilar influence on the 3 natriuretic peptides, and consis-
ently, the ability of each natriuretic peptide to detect an
VEF 40% was not dependent on GFR. Therefore, it
eems that in a chronic HF population: 1) there is no need
or threshold adaption of natriuretic peptides according to
FR; and 2) even in the presence of renal dysfunction, there
s sustained, similar diagnostic performance in all 3 natri-
retic peptides.
A previous study found that NT-proANP had a signifi-
antly lower diagnostic accuracy (AUC: 0.65) than NT-
roBNP (AUC: 0.79) and BNP (AUC: 0.83) in patients
ith left ventricular dysfunction (14). This is in accordance
ith other investigations showing that the inverse relation
f LVEF with BNP was stronger than with ANP or
T-proANP (12,13). In contrast, another study indicated a
etter detection of reduced LVEF by MR-proANP than by
T-proBNP (27). We believe that differences in the ana-
ytical method used are the most probable reasons for the
omparatively high diagnostic power of MR-proANP.
Figure 3 Prediction of Death
Relative importance of MR-proANP, NT-proBNP, and BNP to predict death as
expressed by the partial proportion of explained variation. MR-proANP was a
significantly stronger predictor of death than NT-proBNP and BNP. Abbreviations
as in Figure 1.Conventional NT-proANP assays use an antibody againstT M B N N L G S A S A S D B LVE
F
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May 12, 2009:1783–90 MR-proANP in Chronic HFhe N-terminal region of proANP1-98 combined with a
econd antibody against either the midregion (28), or
-terminal region (29). However, under certain conditions,
he amino-terminal region might be minimally accessible
or antibody binding (6,30), because proANP1-98 can be
ubject to further fragmentation (5,31). We used a concep-
ually different sandwich immunoassay for MR-proANP
amino acids 53 to 90) (15), which has shown more
iochemical stability and might therefore explain the im-
roved diagnostic accuracy of MR-proANP (12–14).
Whereas NT-proBNP has been previously described as a
elatively stable molecule in vitro (32), it is subject to
runcation in vivo (5,6) to an even higher degree than
T-proANP, and especially in NT-proBNP, the smallest
ragments can only be detected by assays directed at the
entral part of the molecule, leading to an underestimation
f up to 40% with conventional assays (5).
rediction of death. There are sparse data comparing the
rognostic power of peptides of the ANP and the BNP
amilies. Tsutamoto et al. (8) found BNP more useful than
NP to predict mortality in chronic HF, which can be
ttributed to the longer plasma half-life of BNP (4,33).
egenhuber et al. (28) found that MR-proANP and
NP were comparable predictors of 1-year survival in
atients hospitalized for acute HF. A similar prognostic
ower of NT-proANP and NT-proBNP to predict mor-
ality was also found after myocardial infarction (29) and
n community-based populations without HF (34).
The reason for the prognostic superiority of MR-
roANP might again be explained by the higher biological
tability of the molecule and the usage of an assay directed
o the midregion of the molecule. Furthermore, it has been
hown that NT-proANP (compared with NT-proBNP and
NP) levels are very robust against variability due to
hysical activity (11). GFR, however, as shown in our study,
oes not seem to be a major confounder of the prognostic
ower of natriuretic peptides and therefore does not account
or any differences in the prediction of death.
tudy limitations. A recent study has shown that the
T-proBNP assay we used markedly underestimates NT-
roBNP values, whereas the BNP assay we used measured
oth BNP and proBNP (7). Therefore, we must assume that
he comparative diagnostic and prognostic performance of
atriuretic peptides reflect assay rather than analyte properties,
o that our conclusions can only refer to the assays used in the
resent study and not to other assays or the natriuretic peptides
s analytes themselves. To answer the question of which
nalyte is better, more sensitive and specific assays for these
olecules are needed.
The study population consisted of patients from previous
rospective studies, of which 100 patients had been ran-
omized to beta-blocker or placebo for approximately 13
onths. Given the high total patient number and the high
bservation time of the present study, we estimate the
nherent bias as minimal.Since MR-proANP is a new marker, no data exist on the
ong-term in vitro stability at80°C. However, extensive in
itro stability testing at various conditions (15) and the high
iagnostic and prognostic accuracy indirectly imply a neg-
igible noise due to in vitro instability.
Our results cannot be extrapolated to a patient population
ithout a history of systolic HF. Especially the diagnostic
ccuracies of natriuretic peptides to detect an LVEF40% are
ikely to be lower in a less selected HF population.
onclusions
n patients with chronic HF due to systolic dysfunction,
R-proANP, NT-proBNP, and BNP are good, compara-
le markers for the assessment of the severity of left
entricular systolic dysfunction and strong independent
redictors of death. Using a new assay directed at the
idregion of the molecule, MR-proANP outperformed
NP and NT-proBNP in the prediction of death. The
easons for these findings might be the new assay technol-
gy and high biological stability of MR-proANP in vivo,
hereas the confounding factor renal dysfunction did not
nfluence the diagnostic or prognostic power of MR-proANP,
T-proBNP, and BNP.
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